ABUS240816C3500
- 0.25
- -0.05-16.67%
Arbutus Biopharma Newsroom
Arbutus Biopharma | 10-Q: Q2 2024 Earnings Report
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Express News | Arbutus Biopharma Corp - if Stipulation Is Granted Would Move Start of the Trial to September 24, 2025
Express News | Arbutus Biopharma Corp - Requesting Amended Case Schedule to Accommodate Certain Outstanding Discovery From Moderna and Third Parties
Express News | JMP Securities Maintains Market Outperform on Arbutus Biopharma, Raises Price Target to $5
Arbutus Biopharma Analyst Ratings
H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
Promising Clinical Advances for Arbutus Biopharma's Imdusiran in Hepatitis B Treatment
Q2 2024 Arbutus Biopharma Corp Earnings Call
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4
Buy Rating Justified by Arbutus Biopharma's Strong Financials and Focused Clinical Strategy
JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5
Arbutus Biopharma: Strategic Focus and Pipeline Promise Drive Buy Rating
Arbutus Biopharma's Promising Hepatitis B Drug Trials
Arbutus to Cut Staff After Halting Hepatitis B Virus Discovery Efforts
Express News | Trading Halt: Halt Status Updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times
Arbutus Biopharma Will Incur One-Time Restructuring Chg of $3M-$4M in 3Q
Arbutus Biopharma Ceasing All Discovery Efforts and Discontinuing IM-PROVE III Clinical Trial >ABUS
Arbutus Terminated Phase 2a Clinical Trial Evaluating Safety, Tolerability and Antiviral Activity of Imdusiran and NA Therapy in Combo With Intermittent Low Doses of Durvalumab >ABUS
Arbutus Biopharma: IM-PROVE I Clinical Trial Demonstrated Undetectable HBsAg in 33% of Patients >ABUS